Lepu Biopharma Co., Ltd.

SEHK:2157 Stock Report

Market Cap: HK$4.9b

Lepu Biopharma Future Growth

Future criteria checks 2/6

Lepu Biopharma is forecast to grow revenue at 65.6% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth42.7%
Revenue growth rate65.6%
Future return on equity-63.4%
Analyst coverage

Low

Last updated04 Sep 2024

Recent future growth updates

No updates

Recent updates

Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

Aug 23
Lepu Biopharma (HKG:2157) Is Making Moderate Use Of Debt

The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%

Jul 18
The Price Is Right For Lepu Biopharma Co., Ltd. (HKG:2157) Even After Diving 27%

Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Jun 03
Lepu Biopharma Co., Ltd. (HKG:2157) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing

Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%

Apr 15
Revenues Not Telling The Story For Lepu Biopharma Co., Ltd. (HKG:2157) After Shares Rise 26%

Earnings and Revenue Growth Forecasts

SEHK:2157 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026989N/AN/AN/A1
12/31/2025270N/AN/AN/A1
12/31/2024280N/AN/AN/A1
6/30/2024205-73-333-290N/A
3/31/2024215-47-313-271N/A
12/31/2023225-22-292-251N/A
9/30/2023197-254-366-307N/A
6/30/2023169-487-440-364N/A
3/31/202392-588-518-422N/A
12/31/202216-689-596-481N/A
9/30/20228-766-617-471N/A
6/30/2022N/A-843-638-460N/A
3/31/2022N/A-927-740-541N/A
12/31/2021N/A-1,011-841-622N/A
12/31/2020N/A-582-734-423N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2157's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2157's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2157's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 2157's revenue (65.6% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).

High Growth Revenue: 2157's revenue (65.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2157 is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y